[go: up one dir, main page]

FR21C1059I2 - Compositions pharmaceutiques - Google Patents

Compositions pharmaceutiques

Info

Publication number
FR21C1059I2
FR21C1059I2 FR21C1059C FR21C1059C FR21C1059I2 FR 21C1059 I2 FR21C1059 I2 FR 21C1059I2 FR 21C1059 C FR21C1059 C FR 21C1059C FR 21C1059 C FR21C1059 C FR 21C1059C FR 21C1059 I2 FR21C1059 I2 FR 21C1059I2
Authority
FR
France
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1059C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhythm Pharmaceuticals Inc
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of FR21C1059I1 publication Critical patent/FR21C1059I1/fr
Application granted granted Critical
Publication of FR21C1059I2 publication Critical patent/FR21C1059I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FR21C1059C 2013-03-15 2021-12-14 Compositions pharmaceutiques Active FR21C1059I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792440P 2013-03-15 2013-03-15
PCT/US2014/029421 WO2014144842A2 (fr) 2013-03-15 2014-03-14 Compositions pharmaceutiques

Publications (2)

Publication Number Publication Date
FR21C1059I1 FR21C1059I1 (fr) 2022-01-21
FR21C1059I2 true FR21C1059I2 (fr) 2022-12-02

Family

ID=50732290

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1059C Active FR21C1059I2 (fr) 2013-03-15 2021-12-14 Compositions pharmaceutiques

Country Status (18)

Country Link
US (2) US11129869B2 (fr)
EP (2) EP2970389B1 (fr)
JP (4) JP6538025B2 (fr)
KR (1) KR102378943B1 (fr)
CN (3) CN105518021A (fr)
AU (5) AU2014228460B2 (fr)
BR (1) BR112015023409B1 (fr)
CA (2) CA2906782C (fr)
DK (1) DK2970389T3 (fr)
ES (1) ES2825076T3 (fr)
FR (1) FR21C1059I2 (fr)
IL (2) IL241378B (fr)
NL (1) NL301149I2 (fr)
NO (1) NO2021051I1 (fr)
PL (1) PL2970389T3 (fr)
PT (1) PT2970389T (fr)
RU (1) RU2690377C2 (fr)
WO (1) WO2014144842A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3988108A1 (fr) 2011-12-29 2022-04-27 Rhythm Pharmaceuticals, Inc. Procédé de traitement de troubles associés au récepteur de la mélanocortine-4 dans des porteurs hétérozygotes
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
CA2906782C (fr) * 2013-03-15 2023-10-03 Rhythm Metabolic, Inc. Compositions pharmaceutiques
EP2991616A4 (fr) * 2013-04-11 2016-11-09 Univ Vanderbilt Polyplexes
WO2016168388A2 (fr) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Thérapies pour l'obésité, le diabète et indications associées
JP6940853B2 (ja) 2015-09-30 2021-09-29 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン４受容体経路関連障害を治療する方法
JP6701572B2 (ja) * 2016-07-05 2020-05-27 株式会社リコー インク、収容容器、画像形成方法及び画像形成装置
JP2019526611A (ja) 2016-09-13 2019-09-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 非タンパク質クロストリジウム毒素組成物
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
MA46990B1 (fr) 2017-08-24 2024-03-29 Novo Nordisk As Compositions glp-1 et ses utilisations
BR112020009648A2 (pt) * 2017-11-15 2020-11-10 Rhythm Pharmaceuticals, Inc. formulações peptídicas de liberação prolongada
WO2019219714A1 (fr) 2018-05-15 2019-11-21 Novo Nordisk A/S Composés capables de se lier au récepteur de la mélanocortine 4
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4
KR102087634B1 (ko) * 2018-10-11 2020-03-11 (주)바이텍 항비만용 조성물
SG11202106847SA (en) * 2019-01-04 2021-07-29 Kineta Chronic Pain Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
TW202535454A (zh) 2020-02-18 2025-09-16 丹麥商諾佛 儂迪克股份有限公司 醫藥配方
CN111718408A (zh) * 2020-07-06 2020-09-29 成都圣诺生物制药有限公司 一种Setmelanotide的制备方法
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
KR20230065921A (ko) * 2021-11-05 2023-05-12 (주)아이엠디팜 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물
WO2023247999A1 (fr) * 2022-06-24 2023-12-28 Mainline Biosciences (Shanghai) Co., Ltd. Modulateurs peptidiques de la douleur et leurs procédés de production et d'utilisation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU6785094A (en) 1993-05-07 1994-12-12 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
EP1441750A4 (fr) 2001-07-11 2006-10-18 Palatin Technologies Inc Peptides lineaires et cycliques specifiques du recepteur de melanocortine
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
EP1644023A2 (fr) * 2003-06-19 2006-04-12 Eli Lilly And Company Agonistes du recepteur 4 de la melanocortine (mc4) et utilisations
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
KR100638041B1 (ko) 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
WO2007008684A2 (fr) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Ligands de recepteurs de melanocortine
EP2286825B1 (fr) * 2005-07-08 2016-09-28 Ipsen Pharma Ligands des récépteurs de la mélanocortine
JP5250026B2 (ja) * 2007-05-25 2013-07-31 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ヒダントインで修飾したメラノコルチン受容体リガンド
AR066175A1 (es) 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
CN101980717A (zh) 2007-11-05 2011-02-23 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
KR20110025974A (ko) * 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 이형제를 함유하는 옥트레오티드 이식물
CN101439182B (zh) * 2008-12-18 2012-02-01 北京大学 一种生长抑素受体介导的肿瘤靶向药物组合物
WO2010144344A2 (fr) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Peptides spécifiques du récepteur de la mélanocortine
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
BR112012002445A2 (pt) 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.
JP2013510881A (ja) 2009-11-16 2013-03-28 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ａｃ−Ａｒｇ−シクロ（Ｃｙｓ−Ｄ−Ａｌａ−Ｈｉｓ−Ｄ−Ｐｈｅ−Ａｒｇ−Ｔｒｐ−Ｃｙｓ）−ＮＨ２の合成のための方法
RU2548753C2 (ru) 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
CA2833676C (fr) 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. Composition a liberation prolongee contenant des peptides en tant que principes actifs
JP2013046596A (ja) 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd 新規な複合体、それを含有する医薬及び癌の治療方法
WO2013033838A1 (fr) * 2011-09-09 2013-03-14 Pharmagap Inc. Formulations liposomales de peptides cationiques et utilisations associées
EP2705835A1 (fr) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CA2906782C (fr) * 2013-03-15 2023-10-03 Rhythm Metabolic, Inc. Compositions pharmaceutiques
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции

Also Published As

Publication number Publication date
AU2023204625A1 (en) 2023-08-03
CN115957297A (zh) 2023-04-14
JP2025004067A (ja) 2025-01-14
US11129869B2 (en) 2021-09-28
JP2016516062A (ja) 2016-06-02
US20220160818A1 (en) 2022-05-26
JP2019189619A (ja) 2019-10-31
AU2019200101B2 (en) 2021-02-04
AU2025213562A1 (en) 2025-08-21
NO2021051I1 (no) 2024-08-05
BR112015023409B1 (pt) 2023-11-28
BR112015023409A2 (pt) 2017-07-18
JP2022065117A (ja) 2022-04-26
CA2906782A1 (fr) 2014-09-18
KR20160020405A (ko) 2016-02-23
AU2014228460B2 (en) 2018-11-01
CN105518021A (zh) 2016-04-20
RU2690377C2 (ru) 2019-06-03
CN115957296A (zh) 2023-04-14
PL2970389T3 (pl) 2021-03-08
CA2906782C (fr) 2023-10-03
FR21C1059I1 (fr) 2022-01-21
EP2970389B1 (fr) 2020-08-19
RU2019116003A (ru) 2019-07-17
JP6538025B2 (ja) 2019-07-03
CA3209602A1 (fr) 2014-09-18
IL288961A (en) 2022-02-01
DK2970389T3 (da) 2020-10-26
AU2019200101A1 (en) 2019-01-31
EP3778623A1 (fr) 2021-02-17
ES2825076T3 (es) 2021-05-14
BR112015023409A8 (pt) 2019-12-03
IL241378B (en) 2022-01-01
EP2970389A2 (fr) 2016-01-20
IL241378A0 (en) 2015-11-30
NL301149I2 (nl) 2022-11-24
US20160022764A1 (en) 2016-01-28
HK1220702A1 (en) 2017-05-12
NL301149I1 (fr) 2021-12-08
WO2014144842A2 (fr) 2014-09-18
AU2014228460A1 (en) 2015-10-01
US12285460B2 (en) 2025-04-29
WO2014144842A3 (fr) 2015-04-09
KR102378943B1 (ko) 2022-03-25
PT2970389T (pt) 2020-10-21
RU2015143965A (ru) 2017-04-24
AU2021202699A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
EP3065716C0 (fr) Formulations
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
LT2968221T (lt) S-ketamino hidrochlorido farmacinė kompozicija
EP2889350A4 (fr) Composition collante-adhésive
EP2953618A4 (fr) Formulations pharmaceutiques inviolables
DK2943549T3 (da) Synergistisk h2s-scavenger-sammensætning
BR112016010669A2 (pt) composição desinfetante
DK3027750T3 (da) Biokatalytisk sammensætning
DK3043778T3 (da) Farmaceutiske sammensætninger, der indeholder refametinib
EP2958994A4 (fr) Composition de vaccin
PL3124018T3 (pl) Doustne formulacje deferazyroksu
EP2961397A4 (fr) Formulations transdermiques
DK2897594T3 (da) Farmaceutisk sammensætning
FR3001392B1 (fr) Composition dermatologique amelioree
LT3079667T (lt) Farmacinės vaisto formos
DK3003401T3 (da) Farmaceutisk præparat
EP2988734C0 (fr) Formulation d'une capsule dure
EP3043648C0 (fr) Compositions pharmaceutiques de bendamustine
DK3060213T3 (da) Farmaceutiske sammensætninger omfattende antibakterielle midler
HRP20171888T1 (hr) Farmaceutski pripravci
EP2986634A4 (fr) Formulations de dhea co-cristallines
MA42111A (fr) Compositions pharmaceutiques topiques
EP3319596A4 (fr) Compositions pharmaceutiques